Insider · CIK 0001627387

Harr Steve

Reports to the SEC for 3 companies · SEATTLE, WA

sec.gov

Transactions

Companies

Filings

CIK

0001627387

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-09	SANASana Biotechnology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−11.5K sh	$3.13	−$36.1K	7,957,070
2026-03-09	SANASana Biotechnology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−12.8K sh	$3.10	−$39.7K	7,944,251
2026-03-07	SANASana Biotechnology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+50K sh	—	—	7,968,596
2026-03-07	SANASana Biotechnology, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−50K sh	—	—	100,000
2026-03-06	SANASana Biotechnology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+41.7K sh	—	—	7,918,596
2026-03-06	SANASana Biotechnology, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−41.7K sh	—	—	125,001
2026-03-05	SANASana Biotechnology, Inc. · Restricted Stock UnitsA Award	Director, President & CEO	AAward	+200K sh	—	—	200,000
2026-03-05	SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+900K sh	—	—	900,000
2025-03-10	SANASana Biotechnology, Inc.F Tax Payment	Director, President & CEO	FTax Payment	−12.8K sh	$2.56	−$32.8K	7,876,930
2025-03-07	SANASana Biotechnology, Inc.M Exercise/Conversion	Director, President & CEO	MExercise/Conversion	+50K sh	—	—	7,889,750
2025-03-07	SANASana Biotechnology, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President & CEO	MExercise/Conversion	−50K sh	—	—	150,000
2025-03-06	SANASana Biotechnology, Inc. · Restricted Stock UnitsA Award	Director, President & CEO	AAward	+167K sh	—	—	166,667
2025-03-06	SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+750K sh	—	—	750,000
2024-03-07	SANASana Biotechnology, Inc. · Restricted Stock UnitsA Award	Director, President & CEO	AAward	+200K sh	—	—	200,000
2024-03-07	SANASana Biotechnology, Inc. · Stock Option (Right to Buy)A Award	Director, President & CEO	AAward	+900K sh	—	—	900,000
2023-03-02	SANASana Biotechnology, Inc. · Stock Options (Right to Buy)A Award	Director, President & CEO	AAward	+650K sh	—	—	650,000
2022-03-03	SANASana Biotechnology, Inc. · Stock Options (Right to Buy)A Award	Director, President & CEO	AAward	+760K sh	—	—	760,000
2021-04-14	SANASana Biotechnology, Inc.G Gift	Director, President & CEO	GGift	−167K sh	—	—	8,006,750
2021-04-14	SANASana Biotechnology, Inc.G Gift	Director, President & CEO	GGift	−167K sh	—	—	7,839,750
2021-02-08	SANASana Biotechnology, Inc.C Conversion	Director, President & CEO	CConversion	+2.03M sh	—	—	8,173,750
2021-02-08	SANASana Biotechnology, Inc. · Series A-1 Convertible Preferred StockC Conversion	Director, President & CEO	CConversion	−1.08M sh	—	—	0
2021-02-08	SANASana Biotechnology, Inc. · Series A-2 Convertible Preferred StockC Conversion	Director, President & CEO	CConversion	−800K sh	—	—	0
2021-02-08	SANASana Biotechnology, Inc. · Series B Convertible Preferred StockC Conversion	Director, President & CEO	CConversion	−156K sh	—	—	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.6K sh	$235.00	−$3.67M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11K sh	$235.00	−$2.59M	0
2019-02-15	Loxo Oncology, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,750 sh	$235.00	−$2.06M	0
2018-06-13	Loxo Oncology, Inc.Director Stock Option (right to buy)A Award	Director	AAward	+8,750 sh	—	—	8,750
2018-03-05	Juno Therapeutics, Inc.U Disposition from Tender	CFO & Head, Corp. Development	UDisposition from Tender	−492K sh	$87.00	−$42.8M	147,162
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−50K sh	$87.00	−$4.35M	97,152
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−20.6K sh	—	—	76,572
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−29.1K sh	—	—	47,437
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−11.5K sh	—	—	35,893
2018-03-05	Juno Therapeutics, Inc.D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−35.9K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−98.8K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−85K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−155K sh	—	—	0
2018-03-05	Juno Therapeutics, Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	CFO & Head, Corp. Development	DDisposition to Issuer	−128K sh	—	—	0
2018-02-27	Juno Therapeutics, Inc.A Award	CFO & Head, Corp. Development	AAward	+11.5K sh	—	—	639,517
2018-02-07	Juno Therapeutics, Inc.F Tax Payment	CFO & Head, Corp. Development	FTax Payment	−1,704 sh	$85.49	−$146K	790,763
2018-02-07	Juno Therapeutics, Inc.G Gift	CFO & Head, Corp. Development	GGift	−163K sh	—	—	627,973
2018-01-31	Juno Therapeutics, Inc.A Award	CFO & Head, Corp. Development	AAward	+29.1K sh	—	—	792,467
2017-12-21	Juno Therapeutics, Inc.M Exercise/Conversion	CFO & Head, Corp. Development	MExercise/Conversion	+8,750 sh	$8.72	+$76.3K	772,082
2017-12-21	Juno Therapeutics, Inc.S Sale	CFO & Head, Corp. Development	SSale	−8,250 sh	$44.74	−$369K	763,832
2017-12-21	Juno Therapeutics, Inc.S Sale	CFO & Head, Corp. Development	SSale	−500 sh	$45.18	−$22.6K	763,332
2017-12-21	Juno Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	CFO & Head, Corp. Development	MExercise/Conversion	−8,750 sh	—	—	98,750
2017-10-20	Juno Therapeutics, Inc.A Award	CFO & Head, Corp. Development	AAward	+35.9K sh	—	—	763,332
2017-07-03	Juno Therapeutics, Inc.M Exercise/Conversion	CFO & Head, Corp. Development	MExercise/Conversion	+8,750 sh	$8.72	+$76.3K	736,189
2017-07-03	Juno Therapeutics, Inc.S Sale	CFO & Head, Corp. Development	SSale	−8,750 sh	$30.00	−$263K	727,439
2017-07-03	Juno Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	CFO & Head, Corp. Development	MExercise/Conversion	−8,750 sh	—	—	107,500
2017-06-27	Juno Therapeutics, Inc.M Exercise/Conversion	CFO & Head, Corp. Development	MExercise/Conversion	+8,750 sh	$8.72	+$76.3K	736,189

Recent filings

Accepted (ET)
Mar 104
Harr Steve0001627387-26-000004
SEC(opens sec.gov)
Mar 64
Harr Steve0001627387-26-000002
SEC(opens sec.gov)
Mar 104
Harr Steve0001562180-25-002271
SEC(opens sec.gov)
Mar 84
Harr Steve0001562180-24-002479
SEC(opens sec.gov)
Mar 34
Harr Steve0001562180-23-002397
SEC(opens sec.gov)
Apr 154
Harr Steve0001562180-22-003413
SEC(opens sec.gov)
Mar 84
Harr Steve0001562180-22-002430
SEC(opens sec.gov)
Feb 104
Harr Steve0000899243-21-005738
SEC(opens sec.gov)

Companies

Address

C/O SANA BIOTECHNOLOGY, INC. 188 EAST BLAINE STREET, SUITE 350

SEATTLE, WA, 98102